Baseimmune <replace with company

logo>

Company Description
Website Baseimmune

Baseimmune is a discovery stage biotech company focused on antigen discovery and

71-75 Shelton Street
vaccine development. London WC2H 9JQ
Headquarters
England, United Kingdom
Investment rationale

Investment Rationale: Joshua Blight (linkedin.com/in/

This company shows promisse due to their technology. They employ the use of AI to try CEO/Founders
joshuablight)
predict outburst of diseases and prepare a vaccine ahead of time. It is truly ann inovative
solution is unlike anything we have seen before. Founded 2019

Focus Area(s) Drug Discovery

Indicators of Progress, Success, and Traction

● “LONDON, UK - Imperial College-based biotech startup Baseimmune has secured $4.8m

Sector(s) Health care
funding to develop the next generation of future-proof universal vaccines against existing and
emerging human and animal health threats including COVID, malaria and African Swine $4.8 million
Fever.” Disclosed funding

Funding stage Seed

● “Baseimmune raises €803K to create variant-proof COVID vaccines; backed by ex- Investors Hoxton ventures, Life Arc, Ciny
Moderna exec, AstraZeneca vaccine co-inventor.”
Baseimmune
(@baseimmune) • Instagram photos and vi
deos
Baseimmune <replace with company
logo>

Solution Features Business Model and Relevant Metrics Founders and Senior Leadership

Problem:
Business Model and Pricing: Name or Title Relevant Background
The founders pioneered the use of computational approaches to
design cross-protective vaccines against various infectious They currently do not have any pricing on their
diseases Joshua Blight Research associate in the
products.
Baum lab
Value Proposition:
Their product is very valuable to customers as it provies them
with a constant and updated vaccine for most Diseases. Given
Phillip Kemlo They made the company to reduce
Relevant Metrics: Earned 3.5 million in their seed- and possibly exterminate diseases
them a sense of security and assurance
round with their lead investors being Hoxton
Solution/Technology: The company uses AI-platform Venture. Ariane C. Gomes Research Assistant at the
models pathogen evolution and immune response to generate Immunopharmacology lab
future- proof vaccines.
Consumer/Customer/User
Revenue : $5.75M
Partnership Details and Proposal

Roadmap:
Consumer profile: The company’s ideal user Previous Partnership Experience:
Baseimmune’s current priporuty is to tacke swine
would be anyone who wanted a vaccine. Vax-Hub | UCL Department of Biochemical
fever in africa. Which is showing promise to their
goal of producing vaccines for all kinds of diseases. Engineering - UCL – University College L
User Experience: They currently do not have any ondon
Consumer reviews, but they show great promise as About (eventscloud.com)
to why a consumer would opt for their product and
keep coming back to it.
Baseimmune <replace with company
logo>

Potential and Risks Competitive Landscape

Risks: The risks of investing in this company is due to the vaccine scare but this can be
easily mititigated through accurate testing and results.

Company History
Logo
● The founders of Baseimmune all have background in medicine
● Josh and Phil are secondary school friends that bonded over building electronic kits and small robots
covered with LEDs and flashing lights in the shed after school
● Josh and Ari met during their PhD’s and bonded over miserable long nights and weekend shifts in the lab.

Overall Analysis and Summary How is the company different from its competitors?

I believe this company Is worth investing into as they have their consumers at heart and ● Their technology unique.
have a grand goal of providing vaccines to all kinds of diseases. Their company shoed ● They reach out to underdeveloped countries early on in their
grate promise and their use of AI technology is truly innovative and is unlike anything company lifetime
currently circulating the market ● They have raised a substantial amount in their seed fund stage
despte being a very young company

Baseimmune closes $4.8m funding round to future-proof vaccines | BioSpace

Baseimmune
raises €803K to create variant-proof COVID vaccines; backed by ex-Moderna exec, AstraZeneca vaccine co-inventor | Silicon Canals